10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
BRISTOL MYERS SQUIBB CO | ||
Ticker: BMY Fiscal Year: 2021 | ||
CONSOLIDATED BALANCE SHEETS | ||
Period Ending Dec 31, 2021 10-K (Filed: Feb 9, 2022) | ||
| (In Millions, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2021 | Dec 31, 2020 | |
| ASSETS | ||
| Current Assets: | ||
| Cash and cash equivalents | $ 13,979 | 14,546 |
| Marketable debt securities | 2,987 | 1,285 |
| Receivables | 9,369 | 8,501 |
| Inventories | 2,095 | 2,074 |
| Other current assets | 4,832 | 3,786 |
| Total Current Assets | 33,262 | 30,192 |
| Property, plant and equipment | 6,049 | 5,886 |
| Goodwill | 20,502 | 20,547 |
| Other intangible assets | 42,527 | 53,243 |
| Deferred income taxes | 1,439 | 1,161 |
| Marketable debt securities | 0 | 433 |
| Other non-current assets | 5,535 | 7,019 |
| Total Assets | 109,314 | 118,481 |
| LIABILITIES | ||
| Current Liabilities: | ||
| Short-term debt obligations | 4,948 | 2,340 |
| Accounts payable | 2,949 | 2,713 |
| Other current liabilities | 13,971 | 14,027 |
| Total Current Liabilities | 21,868 | 19,080 |
| Deferred income taxes | 4,501 | 5,407 |
| Long-term debt | 39,605 | 48,336 |
| Other non-current liabilities | 7,334 | 7,776 |
| Total Liabilities | 73,308 | 80,599 |
| Commitments and contingencies | ||
| EQUITY | ||
| Bristol-Myers Squibb Company Shareholders Equity: | ||
| Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 3,484 in 2021 and 3,484 in 2020, liquidation value of $50 per share | 0 | 0 |
| Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.9 billion issued in 2021 and 2020 | 292 | 292 |
| Capital in excess of par value of stock | 44,361 | 44,325 |
| Accumulated other comprehensive loss | (1,268) | (1,839) |
| Retained earnings | 23,820 | 21,281 |
| Less cost of treasury stock 747 million common shares in 2021 and 679 million common shares in 2020 | (31,259) | (26,237) |
| Total Bristol-Myers Squibb Company Shareholders Equity | 35,946 | 37,822 |
| Noncontrolling interest | 60 | 60 |
| Total Equity | 36,006 | 37,882 |
| Total Liabilities and Equity | 109,314 | 118,481 |
| External Links | |
| BRISTOL MYERS SQUIBB CO (BMY) Fiscal Year 2021 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |